You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sintilimab

Showing 1 - 25 of 152
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency Trial in Guangzhou (drug, radiation, procedure, other)

Active, not recruiting
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Guangzhou, Guangdong, China
    Medical Oncology,Sun Yat-sen University Cancer Center
Jan 29, 2023

Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)

Active, not recruiting
  • Stomach Neoplasms
  • Shanghai, China
    Renji Hospital
Apr 3, 2023

Advanced Biliary Tract Cancer Trial in Changsha (IBI310, sintilimab)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • Changsha, Hunan, China
    Hunan cancer Hospital
Dec 13, 2022

Advanced Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cryoablation, Sintilimab, Lenvatinib)

Recruiting
  • Advanced Intrahepatic Cholangiocarcinoma
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 28, 2023

Stomach Tumors Trial in Wuhan (Fruquintinib, Sintilimab)

Not yet recruiting
  • Stomach Neoplasms
  • Wuhan, Hubei, China
    Wuhan Union Hospital, China
Nov 22, 2022

Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Advanced Biliary Tract Cancer
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 22, 2023

Liver Metastasis Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

Recruiting
  • Liver Metastasis
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Liver Metastases, Colorectal Cancer Metastatic Trial in Shanghai (Sintilimab, Regorafenib, US/CT-guided Percutaneous

Recruiting
  • Liver Metastases
  • Colorectal Cancer Metastatic
  • Sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 8, 2022

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 10, 2022

Hepatocellular Carcinoma Trial in Tianjin (Sintilimab, Bevacizumab, Liver Protective Support Therapy)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 8, 2022

Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin
  • +3 more
  • (no location specified)
Nov 17, 2022

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Sintilimab)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Sintilimab
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 8, 2022

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Cancer of Unknown Primary Site Trial in Houston (Sintilimab)

Recruiting
  • Cancer of Unknown Primary Site
  • Sintilimab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 31, 2022

Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)

Recruiting
  • Breast Cancer
  • sintilimab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 22, 2022

NSCLC (Non-small-cell Lung Cancer) Trial in Changchun (Sintilimab, IBI310)

Recruiting
  • NSCLC (Non-small-cell Lung Cancer)
  • Changchun, Jilin, China
    The First Hospital of Jilin University
Sep 21, 2022

Pancreatic Tumors Trial in Guangzhou (Surufatinib, Sintilimab, AG)

Not yet recruiting
  • Pancreatic Neoplasms
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Jul 28, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Sintilimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)

Recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022

Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Pancreatic Carcinoma Trial in Tianjin (Surufatinib, Sintilimab)

Recruiting
  • Neuroendocrine Tumor Grade 3
  • +2 more
  • Tianjin, Tianjin, China
    Rui Liu
Nov 17, 2022

NSCLC Trial in Hangzhou (sintilimab, pemetrexed, Carboplatin)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • sintilimab
  • +3 more
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Jul 11, 2022

Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Sintilimab
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Hepatocellular Carcinoma Trial in Shanghai (IBI310, Sintilimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Zhongshan Hospital
Sep 16, 2022

Rectal Cancer Trial in Guangzhou (Sintilimab)

Recruiting
  • Rectal Cancer
  • Sintilimab
  • Guangzhou, Guangdong, China
    Department of colorectal surgery, the Sixth Affiliated Hospital,
Jul 11, 2022